A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT04538664
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 308
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation
- Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream
- A female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
- Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)
- Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization is eligible)
- Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD, or radiation pneumonitis
- Participant has a contraindication to the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B: Chemotherapy Alone Carboplatin Participants will receive pemetrexed 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. Arm A: Amivantamab + Chemotherapy Carboplatin Participants will receive pemetrexed 500 milligram per meter square (mg/m\^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. Arm A: Amivantamab + Chemotherapy Pemetrexed Participants will receive pemetrexed 500 milligram per meter square (mg/m\^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. Arm B: Chemotherapy Alone Pemetrexed Participants will receive pemetrexed 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. Arm A: Amivantamab + Chemotherapy Amivantamab Participants will receive pemetrexed 500 milligram per meter square (mg/m\^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) From randomization to either disease progression or death whichever occurs first (up to 29 months) PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) Up to 5 years 3 months Duration of Response (DoR) Up to 5 years 3 months Time to Symptomatic Progression (TTSP) Up to 5 years 3 months Objective Response Rate (ORR) Up to 5 years 3 months Number of Participants Treatment-emergent Adverse Events (TEAEs) From Day 1 to 5 years 2 months Serum Concentration of Amivantamab Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1) Progression-Free Survival After First Subsequent Therapy (PFS2) Up to 5 years 3 months Number of Participants With Clinical Laboratory Abnormalities Up to 5 years 3 months Number of Participants With Vital Signs Abnormalities Up to 5 years 3 months Time to Subsequent Therapy (TST) Up to 5 years 3 months Number of Participants TEAEs With Severity From Day 1 to 5 years 2 months Number of Participants With Anti-Amivantamab Antibodies Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1) Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) From baseline to 5 years 3 months Change From Baseline in Patient Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF) From baseline to 5 years 3 months Number of Participants With Physical Examination Abnormalities Up to 5 years 3 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (228)
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Centrum Onkologii im Prof F Lukaszczyka
🇵🇱Bydgoszcz, Poland
City of Hope
🇺🇸Duarte, California, United States
University of California Irvine
🇺🇸Orange, California, United States
UCLA
🇺🇸Santa Monica, California, United States
Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
H. Lee Moffitt Cancer & Research Institute
🇺🇸Tampa, Florida, United States
University Cancer And Blood Center LLC
🇺🇸Athens, Georgia, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Washington University Medical Center
🇺🇸Saint Louis, Missouri, United States
Regional Cancer Care Associates LLC
🇺🇸East Brunswick, New Jersey, United States
Langone Health at NYC University, NYU School of Medicine
🇺🇸New York, New York, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Sanford Health
🇺🇸Sioux Falls, South Dakota, United States
Texas Oncology Pa
🇺🇸Tyler, Texas, United States
Utah Cancer Specialists
🇺🇸Salt Lake City, Utah, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
Blue Ridge Cancer Care
🇺🇸Salem, Virginia, United States
Chris O'Brien Lifehouse
🇦🇺Camperdown, Australia
St George Hospital
🇦🇺Kogarah, Australia
Cabrini Medical Centre
🇦🇺Malvern, Australia
Sir Charles Gairdner Hospital
🇦🇺Nedlands, Australia
UZ Leuven
🇧🇪Leuven, Belgium
Algemeen Ziekenhuis Delta
🇧🇪Roeselare, Belgium
CHU UCL Namur - Site Godinne
🇧🇪Yvoir, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Cetus Oncologia
🇧🇷Belo Horizonte, Brazil
Ynova Pesquisa Clinica
🇧🇷Florianopolis, Brazil
Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
🇧🇷Ijui, Brazil
Liga Norte Riograndense Contra O Cancer
🇧🇷Natal, Brazil
UPCO Unidade de Pesquisa Clinica em Oncologia
🇧🇷Pelotas, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Ministerio da Saude Instituto Nacional do Cancer
🇧🇷Rio De Janeiro, Brazil
Oncoclinicas Rio de Janeiro S A
🇧🇷Rio de Janeiro, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷Rio de Janeiro, Brazil
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Núcleo de Pesquisa São Camilo
🇧🇷Sao Paulo, Brazil
IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
🇧🇷Sorocaba, Brazil
Hospital Evangélico de Cachoeiro de Itapemirim
🇧🇷Vitoria, Brazil
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
Beijing Cancer Hospital
🇨🇳Beijing, China
Chinese PLA General Hospital
🇨🇳Beijing, China
Beijing Chest hospital, Capital medical university
🇨🇳Beijing, China
Peking University International Hospital
🇨🇳Beijing, China
Jilin cancer hospital
🇨🇳Changchun, China
Hunan Cancer hospital
🇨🇳Changsha, China
The First People's Hospital Of Changzhou
🇨🇳Changzhou, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou, China
The First Affiliated Hospital Sun Yat sen University
🇨🇳Guang Zhou, China
Zhejiang Cancer Hospital
🇨🇳Hang Zhou, China
The First Affiliated Hospital Zhejiang University College of Medicine
🇨🇳Hangzhou, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
🇨🇳Hangzhou, China
Harbin medical university cancer hospital
🇨🇳Harbin, China
Taizhou Hospital of Zhejiang Province
🇨🇳Linhai, China
Nanjing Drum Tower Hospital
🇨🇳Nanjing, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Shanghai East Hospital
🇨🇳Shanghai, China
Shanghai Pulmonary Hospital
🇨🇳Shanghai, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
Cancer hospital Chinese Academy of Medical Sciences, Shenzhen Center
🇨🇳Shenzhen, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
Weifang People's Hospital
🇨🇳Weifang, China
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
🇨🇳Wuhan, China
Hospital of Jiangnan University
🇨🇳Wuxi, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳XI An, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Institut Bergonie
🇫🇷Bordeaux, France
Hospices Civils de Lyon HCL
🇫🇷Bron, France
Centre Georges Francois Leclerc
🇫🇷Dijon, France
Centre Hospitalier Le Mans
🇫🇷le mans Cedex 9, France
CHR Hôpital Calmette
🇫🇷Lille CEDEX, France
CHU Nantes - Hopital Nord Laënnec
🇫🇷NANTES cedex 1, France
Institut Curie
🇫🇷Paris, France
CHU Bordeaux
🇫🇷Pessac, France
HIA Begin
🇫🇷Saint Mande, France
Zentralklinik Bad Berka GmbH
🇩🇪Bad Berka, Germany
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
🇩🇪Gauting, Germany
Thoraxklinik am Universitatsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Onkologische Schwerpunktpraxis
🇩🇪Heilbronn, Germany
Universitaetsklinikum Koeln
🇩🇪Koeln, Germany
Kliniken der Stadt Koeln gGmbH
🇩🇪Koeln, Germany
Bethanien Krankenhaus
🇩🇪Moers, Germany
Pius-Hospital Oldenburg
🇩🇪Oldenburg, Germany
Oncologianova GmbH
🇩🇪Recklinghausen, Germany
Orszagos Koranyi Tbc es Pulmonologiai Intezet
🇭🇺Budapest, Hungary
Mátrai Gyógyintézet-Bronchológia
🇭🇺Gyöngyös, Hungary
Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
🇭🇺Szekesfehervar, Hungary
Markusovszky Egyetemi Oktatokorhaz
🇭🇺Szombathely, Hungary
Tudogyogyintezet Torokbalint
🇭🇺Torokbalint, Hungary
Basavatarakam Indo-American Hospital
🇮🇳Hyderabad, India
Tata Medical Center
🇮🇳Kolkata, India
Tata Memorial Hospital
🇮🇳Mumbai, India
HCG Manavta Cancer Centre
🇮🇳Nasik, India
Rajiv Gandhi Cancer Institute & Research Centre
🇮🇳New Delhi, India
Noble Hospital Pvt Ltd
🇮🇳Pune, India
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Rabin Medical Center
🇮🇱Petah Tikva, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel-Aviv, Israel
A O U Sant Orsola Malpighi
🇮🇹Bologna, Italy
Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
🇮🇹Catania, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
🇮🇹Milano, Italy
IRCCS Ospedale San Raffaele
🇮🇹Milano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
San Gerardo Hospital
🇮🇹Monza, Italy
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
Irccs Gemelli
🇮🇹Roma, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
Juntendo University Hospital
🇯🇵Bunkyo Ku, Japan
Saitama Medical University International Medical Center
🇯🇵Hidaka, Japan
National Hospital Organization Himeji Medical Center
🇯🇵Himeji, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Kishiwada City Hospital
🇯🇵Kishiwada, Japan
Kobe City Medical Center General Hospital
🇯🇵Kobe, Japan
Kurashiki Central Hospital
🇯🇵Kurashiki, Japan
Kurume University Hospital
🇯🇵Kurume, Japan
Matsusaka Municipal Hospital
🇯🇵Matsusaka, Japan
Aichi Cancer Center Hospital
🇯🇵Nagoya Shi, Japan
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya-shi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Kindai University Hospital
🇯🇵Osaka Sayama shi, Japan
Kitasato University Hospital
🇯🇵Sagamihara, Japan
Hokkaido University Hospital
🇯🇵Sapporo-shi, Japan
Iwate Medical University Hospital
🇯🇵Shiwa-gun, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Ehime University Hospital
🇯🇵Toon-shi, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
National Hospital Organization Yamaguchi Ube Medical Center
🇯🇵Yamaguchi, Japan
Inje University Haeundae Paik Hospital
🇰🇷Busan, Korea, Republic of
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
GyeongSang National University Hospital
🇰🇷Gyeongsangnam-do, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Pulau Pinang
🇲🇾George Town, Malaysia
Hospital Sultan Ismail
🇲🇾Johor Bahru, Malaysia
Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Centro Oncologico de Chihuahua
🇲🇽Chihuahua, Mexico
Mexico Centre for Clinical Research, S.A. de C.V.
🇲🇽Ciudad de Mexico, Mexico
Médica Sur
🇲🇽Ciudad de Mexico, Mexico
Instituto Nacional de Cancerologia
🇲🇽Ciudad de Mexico, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Mexico
Health Pharma Professional Research
🇲🇽Mexico, Mexico
i Can Oncology Center
🇲🇽Monterrey, Mexico
Oncologia Integral Satelite
🇲🇽Naucalpan, Mexico
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Szpitale Pomorskie Sp z o o
🇵🇱Gdynia, Poland
Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
🇵🇱Olsztyn, Poland
Private Specialist Hospitals - MedPolonia
🇵🇱Poznan, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Hosp. Cuf Descobertas
🇵🇹Lisboa, Portugal
Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
🇵🇹Lisboa, Portugal
Centro Hospitalar Universitario do Porto, EPE
🇵🇹Porto, Portugal
Instituto Portugues de Oncologia
🇵🇹Porto, Portugal
Centro Hospitalar de Vila Nova de Gaia Espinho E P E
🇵🇹Vila Nova de Gaia, Portugal
Pan American Center for Oncology Trials LLC
🇵🇷Rio Piedras, Puerto Rico
Irkutsk Regional Oncology Dispensary
🇷🇺Irkutsk, Russian Federation
Moscow City Oncology Hospital № 62
🇷🇺Krasnogorsk, Russian Federation
Krasnoyarsk Regional Oncology Dispensary
🇷🇺Krasnoyarsk, Russian Federation
Leningrad Regional Oncology Dispensary
🇷🇺Kuzmolovsky, Russian Federation
MCK
🇷🇺Moscow, Russian Federation
City Clinical Hospital #1
🇷🇺Nalchik, Russian Federation
Nizhny Novgorod Regional Oncological Dispensary
🇷🇺Nizhniy Novgorod, Russian Federation
N.N. Petrov Research Institute Of Oncology
🇷🇺Saint Petersburg, Russian Federation
Leningrad Regional Clinical Hospital
🇷🇺Saint-Petersburg, Russian Federation
Oncology Medical Clinics AV Medical group
🇷🇺St-Petersburg, Russian Federation
Tomsk Cancer Research Institute
🇷🇺Tomsk, Russian Federation
Bashkir State Medical University
🇷🇺Ufa, Russian Federation
Yaroslavl Regional Clinical Oncology Hospital
🇷🇺Yaroslavl, Russian Federation
Hosp Univ A Coruna
🇪🇸A Coruna, Spain
Inst. Cat. D'Oncologia-Badalona
🇪🇸Badalona, Spain
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp. Univ. Quiron Dexeus
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp. Univ. de Burgos
🇪🇸Burgos, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. Ramon Y Cajal
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp. Univ. Pta. de Hierro Majadahonda
🇪🇸Majadahonda, Spain
Hosp Virgen de La Victoria
🇪🇸Málaga, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Hosp. Virgen Del Rocio
🇪🇸Seville, Spain
Hosp. Clinico Univ. Lozano Blesa
🇪🇸Zaragoza, Spain
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Chang Gung Medical Foundation
🇨🇳Kaohsiung, Taiwan
Taipei Medical University Shuang Ho Hospital
🇨🇳New Taipei, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Phramongkutklao Hospital and Medical College
🇹🇭Bangkok, Thailand
Siriraj Hospital
🇹🇭Bangkok, Thailand
Songklanagarind Hospital, Prince of Songkla University
🇹🇭Songkla, Thailand
Adana City Hospital
🇹🇷Adana, Turkey
Başkent University Medical Faculty Adana Application and Research Center
🇹🇷Adana, Turkey
Gazi University Hospital
🇹🇷Ankara, Turkey
Ankara Bilkent City Hospital
🇹🇷Ankara, Turkey
Trakya University Medical Faculty
🇹🇷Edirne, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
🇹🇷Istanbul, Turkey
Medipol Mega University Hospital
🇹🇷Istanbul, Turkey
Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
🇹🇷Istanbul, Turkey
Izmir Medical Park Hospital
🇹🇷Izmir, Turkey
Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
🇺🇦Dnipro, Ukraine
Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
🇺🇦Kyiv, Ukraine
National Cancer Institute
🇺🇦Kyiv, Ukraine
Edinburgh Cancer Centre Western General
🇬🇧Edinburgh, United Kingdom
The Royal Marsden NHS Trust
🇬🇧Sutton, United Kingdom